Open access
Open access
Powered by Google Translator Translator

Family Medicine

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

13 Aug, 2021 | 09:58h | UTC

Could This Be Our First Effective, Inexpensive, Widely Available Outpatient Treatment for COVID-19? – HIV and ID Observations

Related: Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

 

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

13 Aug, 2021 | 10:01h | UTC

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison – American Family Physician

Related:

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children

 

Opinion: Time for a smart approach to boosters.

13 Aug, 2021 | 09:51h | UTC

Time for a Smart Approach to Boosters – Think Global Health

 

Study shows clinicians significantly overestimate the benefits of treatment to individual patients.

13 Aug, 2021 | 08:58h | UTC

Clinician Conceptualization of the Benefits of Treatments for Individual Patients – JAMA Network Open

 

Commentary on Twitter

 

Cohort study: Long-term night shift work is associated with the risk of atrial fibrillation and coronary heart disease.

13 Aug, 2021 | 08:56h | UTC

Long-term night shift work is associated with the risk of atrial fibrillation and coronary heart disease – European Heart Journal

 

Commentary on Twitter

 

M-A of randomized trials: proton pump inhibitors for gastro-esophageal reflux disease does not improve outcomes in patients with asthma.

13 Aug, 2021 | 08:53h | UTC

Randomised trials of proton pump inhibitors for gastro-oesophageal reflux disease in patients with asthma: an updated systematic review and meta-analysis – BMJ Open

 

RCT: Evaluation of Moderna mRNA vaccine in adolescents.

12 Aug, 2021 | 09:58h | UTC

Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents – New England Journal of Medicine

Related:

Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.

RCT: Pfizer-BioNTech Covid-19 vaccine shows 100% efficacy in adolescents – mainly transient mild-to-moderate reactogenicity was frequently observed, such as injection-site pain (in 79 to 86% of participants), fatigue (in 60 to 66%), and headache (in 55 to 65%).

 

Commentaries on Twitter

 

[Preprint] Pfizer vs. Moderna COVID-19 vaccine effectiveness against the Delta variant in Qatar – Effectiveness against symptomatic disease due to Delta was 53.5% for Pfizer and 84.8% for Moderna; effectiveness against severe disease due to Delta was 89.7% for Pfizer and 100.0% for Moderna.

12 Aug, 2021 | 09:53h | UTC

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar – medRxiv

Related:

Study shows AstraZeneca and Pfizer vaccines are effective against Delta variant, but both doses are needed.

 

Commentary on Twitter

 

Video: Frequently Asked COVID-19 Vaccine Questions – August 2021 Update.

12 Aug, 2021 | 08:59h | UTC

Frequently Asked COVID-19 Vaccine Questions – August 2021 Update – JAMA

 

2021 guidelines for management of venous thromboembolism in Latin America.

12 Aug, 2021 | 08:56h | UTC

ASH, ABHH, ACHO, Grupo CAHT, Grupo  CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America – Blood Advances

 

Review: Diagnosis of uncomplicated and complicated appendicitis in adults.

12 Aug, 2021 | 08:45h | UTC

Diagnosis of Uncomplicated and Complicated Appendicitis in Adults – Scandinavian Journal of Surgery

 

Brief review: Nails in systemic disease.

12 Aug, 2021 | 08:40h | UTC

Nails in systemic disease – Clinical Medicine Journal

 

Brief review: Immunobullous disease.

12 Aug, 2021 | 08:37h | UTC

Immunobullous disease – Clinical Medicine Journal

 

Psoriasis: a brief overview.

12 Aug, 2021 | 08:39h | UTC

Psoriasis: a brief overview – Clinical Medicine Journal

 

Brief review: Advances in atopic dermatitis.

12 Aug, 2021 | 08:32h | UTC

Advances in atopic dermatitis – Clinical Medicine Journal

 

Cutaneous manifestations of infections: an update for general physicians.

12 Aug, 2021 | 08:36h | UTC

Cutaneous manifestations of infections: an update for general physicians – Clinical Medicine Journal

 

M-A: Asymptomatic SARS-CoV-2 infection – “we estimate that the percentage of infections that never developed clinical symptoms, and thus were truly asymptomatic, was 35.1%”.

11 Aug, 2021 | 08:49h | UTC

Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis – Proceedings of the National Academy of Sciences

 

Commentary on Twitter

 

PRINCIPLE RCT: Inhaled budesonide improves time to recovery from COVID-19 in people at high risk of complications in the community.

11 Aug, 2021 | 08:52h | UTC

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial – The Lancet

Invited Commentary: The use of inhaled corticosteroids in early-stage COVID-19

 

M-A: More than 50 long-term effects of COVID-19.

11 Aug, 2021 | 08:47h | UTC

More than 50 long-term effects of COVID-19: a systematic review and meta-analysis – Scientific Reports

Related:

Illness duration and symptom profile in symptomatic school-aged children tested for SARS-CoV-2 – “Only 25 (1.8%) of 1379 children experienced symptoms for at least 56 days.”

Cohort study: Risk factors for long covid in previously hospitalized children.

Viewpoint: The road to addressing Long Covid.

Review: Long covid—mechanisms, risk factors, and management.

Review: Symptoms, complications and management of long COVID.

Long Covid: fatigue, post-exertional malaise, and cognitive dysfunction are the most common symptoms, according to an international survey.

Studies elucidate poorly understood long COVID.

Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents – “This study found a low prevalence of symptoms compatible with long COVID in a randomly selected cohort of children assessed 6 months after serologic testing”.

Long Covid: 39% of patients report persistent symptoms more than seven months after diagnosis of COVID-19 in an outpatient setting.

[Preprint] Long Covid: Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people.

Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms.

Long Covid: Half of young adults with COVID-19 have persistent symptoms 6 months after, study finds.

[Preprint] Long Covid: Third of people infected have long term symptoms.

Opinion | Causation or confounding: why controls are critical for characterizing long COVID – “Many of the self-reported symptoms, such as intermittent headaches or tiredness, are nonspecific and prevalent in the general population”.

Almost 25% of COVID-19 patients develop long-lasting symptoms, according to a new report.

Perspective | The four most urgent questions about long COVID.

Systematic review: Frequency, signs and symptoms, and criteria adopted for long COVID-19.

Report: 376,000 people in UK have had long Covid symptoms for at least a year.

Systematic review of 45 studies including 9751 participants, most of which were hospitalized, found 73% had at least 1 persistent symptom for weeks after Covid-19.

COVID Morbidity – The emerging burden of long COVID is significant, and needs to be considered when evaluating the risk vs. benefit of pandemic measures.

One year after hospital discharge due to SARS-CoV-2 Infection, the prevalence of long-term cough, chest pain, dyspnea, and fatigue was 2.5%, 6.5%, 23.3%, and 61.2%, respectively

Population-based cohort study: Non-hospitalized COVID-19 patients have low-risk of serious long-term effects, but visits to general practitioners and outpatient hospital visits are increased.

One third of patients hospitalized with COVID-19 have lung changes after a year

Long Covid: Largest post-acute COVID-19 study to date examined the health outcomes in more than 73,000 people who’d had COVID-19 and were not hospitalized

Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease

Perspective | They Tested Negative for Covid. Still, They Have Long Covid Symptoms.

Large study finds 1 in 3 Covid-19 survivors have subsequent mental health and neurological conditions

Cohort study: One in ten have long-term effects 8 months following mild COVID-19

Long Covid Implications for the workplace

Long Covid in the UK – More than a million affected in February, survey suggests

Covid-19: Middle aged women face greater risk of debilitating long term symptoms

Persistent neurologic symptoms and cognitive dysfunction in non‐hospitalized Covid‐19 “long haulers”

Opinion | We need to start thinking more critically — and speaking more cautiously — about long Covid

Review | Post-acute COVID-19 syndrome

Long Covid | Four-month clinical status of a cohort of patients after hospitalization for COVID-19

Perspective | Long Covid isn’t as unique as we thought

Attributes and predictors of long COVID

WHO Report: Preparing for Long COVID 2021

Long Covid: Sequelae in adults at 6 Months after COVID-19 infection

How many people get ‘long COVID’ – and who is most at risk?

Long Covid: Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge

Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline

Patients, clinicians seek answers to the mystery of ‘Long COVID’

Long Covid: 6-month consequences of COVID-19 in patients discharged from hospital

[Preprint] Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact

NICE Guideline: Managing the long-term effects of COVID-19

 

Commentary on Twitter

https://twitter.com/svillapol/status/1425032774793285648

 

CDC Report: COVID-19 morbidity and mortality far exceed the potential risks of rare side effects caused by vaccines.

11 Aug, 2021 | 08:45h | UTC

Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021 – CDC Morbidity and Mortality Weekly Report

 

USPSTF Statement recommends screening for gestational diabetes in asymptomatic pregnant persons at 24 weeks of gestation or after.

11 Aug, 2021 | 08:35h | UTC

Final Recommendation Statement: Gestational Diabetes: Screening – U.S. Preventive Services Task Force

Evidence report: Screening for Gestational Diabetes: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force – JAMA

Editorial: Screening for Gestational Diabetes – JAMA

Author interview: USPSTF Recommendation: Screening for Gestational Diabetes

JAMA Patient Page: Screening for Gestational Diabetes

 

New WHO toolkit promotes inclusion of people with dementia in society.

11 Aug, 2021 | 08:31h | UTC

New WHO toolkit promotes inclusion of people with dementia in society – World Health Organization

See Guidance: Towards a dementia inclusive society: WHO toolkit for dementia-friendly initiatives (DFIs) – World Health Organization

 

Commentary on Twitter (thread – click for more)

 

M-A: Child and youth mental health problems have doubled during COVID-19.

10 Aug, 2021 | 10:03h | UTC

Commentary: Child and youth mental health problems have doubled during COVID-19 – The Conversation

Original study: Global Prevalence of Depressive and Anxiety Symptoms in Children and Adolescents During COVID-19: A Meta-analysis – JAMA Pediatrics

Editorial: Addressing the Global Crisis of Child and Adolescent Mental Health – JAMA Pediatrics

Related:

More data on the harmful effects of the COVID-19 pandemic on the mental health of adolescents.

COVID has caused ‘mass trauma,’ worsening mental health globally.

COVID’s mental-health toll: how scientists are tracking a surge in depression

CDC Report: Mental health-related emergency department visits among children aged under 18 years raised during the COVID-19 Pandemic

WHO: COVID-19 disrupting mental health services in most countries

 

Commentary on Twitter (thread – click for more)

 

Systematic review: Prescribing practices, patterns, and potential harms in patients receiving palliative care – “many patients receiving palliative care receive multiple medications closer to the time of death”.

11 Aug, 2021 | 08:23h | UTC

Prescribing practices, patterns, and potential harms in patients receiving palliative care: A systematic scoping review – Exploratory Research in Clinical and Social Pharmacy

 

Commentary on Twitter

 

[Preprint] Phase 1/2 RCT: A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac.

10 Aug, 2021 | 09:58h | UTC

A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial – medRxiv

 

Commentary on Twitter

https://twitter.com/hildabast/status/1424644994120372224

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.